Alcon Research, Ltd.

Alcon Laboratories, Inc.

Novartis Ag

Alcon, Inc.

Alcon Manufacturing, Ltd.

Alcon Universal Ltd.

Merlion Pharmaceuticals Pte. Ltd.

Bhagwati P Kabra

Masood A Chowhan

Janet D Howie

Wesley Wehsin Han

Malay Ghosh

L Wayne Schneider

Rajan Bawa

Ruma P Sarkar

James E Teague

Rex E Hall

Mandar V Shah

Laman L Alani

Gustav Graff

Gerald D Cagle

Rajni Jani

Alan L Weiner

John C Lang

Kerry L Markwardt

David Allen Marsh

Francisco Javier Galán

Youqin Tian

Carmen Martinez

Nuria Carreras

Nuria Jiménez

Mark J Bridle

Mónica Cuchi

Brent G Boudreaux

Bryan H Huynh

Adrian Sauceda

Elena González Puig

Mridvika

Ruma Sarkar

Carmen MARTÍNEZ

Francisco Javier GALÁN

Carmen Martínez

Mridvika Narda

Elena Puig GONZÀLEZ

Nuria Jimenez

Monica Cuchi

Elena Gonzalez Puig

The present invention is directed to the provision of a pharmaceutical suspension. The suspension includes high molecular weight polyethylene glycol as a suspending agent. The suspension also typically includes an antimicrobial agent (e.g., polymeric quaternary ammonium compound), an antimicrobial system (e.g., borate/polyol complex system) or both. The suspension has been found particularly useful as an ophthalmic suspension, but can be used in other instances as well.

Pharmaceutical suspension

The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a suspension composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin free base or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.

Finafloxacin suspension compositions

The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of benzalkonium chloride.

Aqueous pharmaceutical compositions containing borate-polyol complexes

The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

Pharmaceutical compositions having desirable bioavailability

The present invention relates to development of efficacious pharmaceutical implant compositions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000.

Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye

The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include a balance of ingredients that allow for the formation of ophthalmic compositions that include an anionic drug and exhibit desired characteristics such as stability, preservation efficacy, desired pH, desired osmolality, combinations thereof or the like.

Aqueous ophthalmic compositions containing anionic therapeutic agents

The present invention is directed to a pulsatile ophthalmic peri-corneal drug delivery device. The device includes an annular body and a mechanism for releasing multiple separate and distinct doses of a therapeutic composition over an extended period of time.

Pulsatile peri-corneal drug delivery device

Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.

Topical ophthalmic compositions containing tobramycin and dexamethasone

The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred. Limiting the amount of divalent metals other than zinc and the amount of ionized salts present has also been determined to be important to maximize the antimicrobial activity of the balanced buffer systems.

Self-preserved aqueous pharmaceutical compositions

The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borat or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred. Limiting the amount of divalent metals other than zinc and the amount of ionized salts present has also been determined to be important to maximize the antimicrobial activity of the balanced buffer systems.

Self preserved aqueous pharmaceutical compositions

Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-guage needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Solid or semi-solid intraocular implant compositions are disclosed. The compositions contain a lipophilic compound but lack a polymeric ingredient.

Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use

Growing community of inventors

Euless, TX, United States of America

Bhagwati P Kabra